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Objectives
The purpose of this work is to understand the current situation of
gene therapy in Haemophilia B and to assess the upcoming solutions
proposed to solve the problems appeared in the clinical trials, after
the vector transfer.
Methods
The articles used for the realization of this review were search
scientific databases using the following key-words: haemphilia B,
gene therapy, AAV vectors, immune response and clinical trials. For
the elaboration of the final work, the most relevant information was
selected.
Introduction
Haemophilia B is an X-linked bleeding disorder 
It is a good target for gene therapy:
Cause: mutations in the gene encoding blood coagulation 
factor IX. 
Prevalence: 1/20.000 live male adults worldwide. 
Current treatment: intravenous infusion of clotting factor 
concentrates. 
Economic cost: $200.000 per year for an adult with 
severe disease treated prophylactically.  
Classification: severe (<1%), moderate  (1-5%) or mild 
(>5%) according to circulating FIX levels. 
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Results - The two main clinical trials
Trial / 
Year
Pre-clinical studies
Vector and route of 
administration 
Subjects Results Problems and side effects Conclusion
Manno et 
al, 2006
Studies showing long-lasting 
expression of FIX levels in dogs 
injected with a single infusion of 
rAAV vector either into the portal 
vein or the hepatic artery. 
• rAAV-2 vector containing hFIX gene 
with a liver-specific promoter (AAT
promoter, APOE enhancer and 
elements of HCR). 
• Vector delivered through the 
hepatic artery. 
7 subjects divided in 3 
dose-cohort: 
•8x1010 vg/kg
•4x1011 vg/kg
•2x1012 vg/kg
A subject reached a circulating FIX 
of 11.8% which persisted during 
10 weeks. 
• Asymptomatic transaminitis 4 weeks 
after vector infusion. 
•Presence of neutralizing antibodies to 
AAV.   
• No formation of inhibitory antibodies 
to the transgene product. 
Expression of FIX in liver can be 
achieved after an AAV2 injection.  
Confirmation of a T cell response 
against capsid antigens, not seen in 
animals , that destroyed transduced 
hepatocytes. 
• Subjects in the high cohort
FIX expression after a intravenous 
2003 – First clinical trial in humans: 
intramuscular injection of a rAAV vector 
encoding FIX transgene. 
90s – Several studies in mice and dogs 
using non-viral, retroviral adenoviral and 
AAV vectors. 
1989 – FIX detected in mice circulation after  
transplanting fibroblasts transduced ex vivo
with a retrovirus containing hFIX. 
Gene therapy pretends to add a correct gene, which will 
supply the missing protein
Adeno-associated viruses
• Small, non – pathogenic and single-stranded DNA viruses
• Replication – defective: need of a helper virus for replication and completion 
of  their life cycle.  
• Genome composed by two genes: rep and cap. 
AAV vectors
• A therapeutic  expression cassette replaces rep and cap genes, leaving the viral 
ITRs as the only viral sequences. 
• Transduction of non-dividing cells, remaining in an episomal form. 
• Limited packaging capacity (4700 nucleotides).  
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Safety studies on macaques that 
maintained a stable level of 
transgene expression for 5 years 
after being transduced with a 
scAAV vector directed to liver. 
• scAAV-8 vector containing the PL 
promoter and a codon-optimized
hFIX.
•Vector delivered through 
intravenous infusion.   
6 subjects divided in 3 
dose-cohort: 
• 2x1011 vg/kg
• 6x1011 vg/kg
• 2x1012 vg/kg 
Subjects in the low and medium 
cohort experienced a modest 
improvement of circulating FIX 
levels  (between 1-3%). 
Subjects in the high cohort, 
achieved FIX levels of 7% and 8-
12% respectively declining until 
3% and 5%, but persisting for 6 
months and more than a year. 
experienced a rise in liver enzymes 
(asymptomatic transaminitis), reduced 
after a steroid treatment. 
• Dose-dependent AAV8 capsid-
specific T cell response after gene 
transfer.  
• No formation of neutralizing 
antibodies to the transgene product. 
infusion remains stable during months  
and, for one case, the level achieved 
reaches about 5%, which results 
enough to convert haemophilia from 
severe to mild. 
A larger number of participants will be 
needed to evaluate the clinical 
significance of the elevation in 
aminotransferase levels.    
Asymptomatic transaminitis resulting in the destruction of the transduced cells
• In contrast to experimental animals, AAV2 naturally infects humans during childhood together with a
helper virus. This causes activation of the innate immune system and forms CD8+ T cells directed to the
antigens. After the infection, a small pool of memory T cells are maintained and can be reactivated in a
reexposure of AAV capsid, destroying the transduced cells.
• Memory CD8+ T cells are activated though the recognition of capsid-derived peptides presented on
the cell surface in MHC class I.
• When hepatocytes are destroyed, cytosolic enzimes are released to the circulation causing
transaminitis.
• The transaminitis can be solved administrating a short-term immunosuppressant treatment that
blocks the response to capsid antigens until they are completely cleared from the transduced cells.
Formation of antibodies against the transgene product
Some patients (about 3%) develop antibodies against the therapeutic protein. Studies in non-human
primates showed an eradication of inhibitory Ab against human FIX after a treatment with cyclosporine
A and rituximab (Mingozzi F et al, 2012).
Pre-existing neutralizing antibodies against AAVs
Antibodies against AAVs remain in most of the population, after being infected. This causes a decrease
in transduction efficacy which could be solved creating an engineered capsid.
AAV2(Y-F) mutant capsid preserve gene expression and minimize the loss of transduced hepatocytes
because:
- There are no pre-existing neutralizing antibodies against the engineered capsid.
- The specific mutation causes a decrease in proteasome-mediated degradation of AAV2 vectors.
Zhong Li et al, 2012
Increasing the efficacy of gene transfer : use of Factor IX Padua
Factor IX (R338L) gene results in a hyperfunctional protein (known as factor Padua), with a clotting
activity of eight times the normal level (Simoni P et al, 2009). The use of this mutant gene in the
therapeutic cassette could increase the efficacy of gene transfer.
 Liver-directed gene transfer using AAV vectors could provide long-term expression of FIX, enable
to convert haemophilia B from a severe to a mild form.
 Immune response to the transduced cells represents the main barrier. Nevertheless, it could be
managed through:
Immunosuppressant treatments
Engineered capsids
 Trials enrolling more subjects will be crucial to assess new approaches (e.g. factor IX Padua) and
individual variations of the therapy.
Figure 1 │Explanation of the rise in liver enzymes observed in the clinical trial. Mingozzi FH et al, 2011. 
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